GBD 2019 MDC. Global, regional, and national burden of 12 mental disorders in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet Psychiatry. 2022;9:137–50.

Article  Google Scholar 

Solmi M SG, Mavridis D, Correll CU, Dragioti E, Guimond S, et al. Incidence, prevalence, and global burden of schizophrenia—data, with critical appraisal, from the Global Burden of Disease (GBD) 2019. Mol Psychiatry. 2023.

Keepers GA, Fochtmann LJ, Anzia JM, Benjamin S, Lyness JM, Mojtabai R, et al. The American Psychiatric Association practice guideline for the treatment of patients with schizophrenia. Am J Psychiatry. 2020;177:868–72.

Article  PubMed  Google Scholar 

Correll CU, Howes OD. Treatment-resistant schizophrenia: definition, predictors, and therapy options. J Clin Psychiatry. 2021; 82:MY20096AH1C.

Diniz E, Fonseca L, Rocha D, Trevizol A, Cerqueira R, Ortiz B, et al. Treatment resistance in schizophrenia: a meta-analysis of prevalence and correlates. Braz J Psychiatry. 2023;45:448–58.

PubMed  PubMed Central  Google Scholar 

Correll CU, Solmi M, Cortese S, Fava M, Højlund M, Kraemer HC, et al. The future of psychopharmacology: a critical appraisal of ongoing phase 2/3 trials, and of some current trends aiming to de‐risk trial programmes of novel agents. World Psychiatry. 2023;22:48–74.

Article  PubMed  PubMed Central  Google Scholar 

Berk M, Marx W, Nierenberg AA. The aggregation of marginal gains: a pragmatic philosophy of clinical care in psychiatry. World Psychiatry. 2024;23:291–292.

Correll CU, Rubio JM, Inczedy-Farkas G, Birnbaum ML, Kane JM, Leucht S. Efficacy of 42 pharmacologic cotreatment strategies added to antipsychotic monotherapy in schizophrenia: systematic overview and quality appraisal of the meta-analytic evidence. JAMA Psychiatry. 2017;74:675–84.

Article  PubMed  PubMed Central  Google Scholar 

Seetharaman M, Krishnan G, Schneider RH. The future of medicine: frontiers in integrative health and medicine. Medicina. 2021;57:1303.

Tsiaka T, Kritsi E, Tsiantas K, Christodoulou P, Sinanoglou VJ, Zoumpoulakis P. Design and development of novel nutraceuticals: current trends and methodologies. Nutraceuticals. 2022;2:71–90.

Article  Google Scholar 

Sarris J, Ravindran A, Yatham LN, Marx W, Rucklidge JJ, McIntyre RS et al. Clinician guidelines for the treatment of psychiatric disorders with nutraceuticals and phytoceuticals: The World Federation of Societies of Biological Psychiatry (WFSBP) and Canadian Network for Mood and Anxiety Treatments (CANMAT) Taskforce. World J Biol Psychiatry. 2022:1–32.

DeFelice SL. The nutraceutical revolution: its impact on food industry R&D. Trends Food Sci Technol. 1995;6:59–61.

Article  CAS  Google Scholar 

Lee SY, Shin YW, Hahm KB. Phytoceuticals: mighty but ignored weapons against Helicobacter pylori infection. J Dig Dis. 2008;9:129–39.

Article  CAS  PubMed  Google Scholar 

Firth J, Teasdale SB, Allott K, Siskind D, Marx W, Cotter J, et al. The efficacy and safety of nutrient supplements in the treatment of mental disorders: a meta-review of meta-analyses of randomized controlled trials. World Psychiatry. 2019;18:308–24.

Article  PubMed  PubMed Central  Google Scholar 

Sarris J, Marx W, Ashton MM, Ng CH, Galvao-Coelho N, Ayati Z, et al. Plant-based medicines (Phytoceuticals) in the treatment of psychiatric disorders: a meta-review of meta-analyses of randomized controlled trials: Les médicaments à base de plantes (phytoceutiques) dans le traitement des troubles psychiatriques: une méta-revue des méta-analyses d’essais randomisés contrôlés. Can J Psychiatry. 2021;66:849–62.

Article  PubMed  PubMed Central  Google Scholar 

Xu X, Shao G, Zhang X, Hu Y, Huang J, Su Y, et al. The efficacy of nutritional supplements for the adjunctive treatment of schizophrenia in adults: A systematic review and network meta-analysis. Psychiatry Res. 2022;311:114500.

Article  PubMed  Google Scholar 

Hutton B, Salanti G, Caldwell DM, Chaimani A, Schmid CH, Cameron C, et al. The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. Ann Intern Med. 2015;162:777–84.

Article  PubMed  Google Scholar 

Sterne JAC, Savović J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366:l4898.

Article  PubMed  Google Scholar 

Nikolakopoulou A, Higgins JP, Papakonstantinou T, Chaimani A, Del Giovane C, Egger M, et al. CINeMA: an approach for assessing confidence in the results of a network meta-analysis. PLoS Med. 2020;17:e1003082.

Article  PubMed  PubMed Central  Google Scholar 

Higgins JPT TJ, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane handbook for systematic reviews of interventions version 6.3 (updated February 2022), 2022.

Solmi M, Wade TD, Byrne S, Del Giovane C, Fairburn CG, Ostinelli EG, et al. Comparative efficacy and acceptability of psychological interventions for the treatment of adult outpatients with anorexia nervosa: a systematic review and network meta-analysis. Lancet Psychiatry. 2021;8:215–24.

Article  CAS  PubMed  Google Scholar 

Levine J, Stahl Z, Sela BA, Ruderman V, Shumaico O, Babushkin I, et al. Homocysteine-reducing strategies improve symptoms in chronic schizophrenic patients with hyperhomocysteinemia. Biol Psychiatry. 2006;60:265–9.

Article  CAS  PubMed  Google Scholar 

Hosseininasab M, Zarghami M, Mazhari S, Salehifar E, Moosazadeh M, Fariborzifar A, et al. Nanocurcumin as an add-on to antipsychotic drugs for treatment of negative symptoms in patients with chronic schizophrenia: a randomized, double-blind, placebo-controlled study. J Clin Psychopharmacol. 2021;41:25–30.

Article  CAS  PubMed  Google Scholar 

Miodownik C, Lerner V, Kudkaeva N, Lerner PP, Pashinian A, Bersudsky Y, et al. Curcumin as add-on to antipsychotic treatment in patients with chronic schizophrenia: A randomized, double-blind, placebo-controlled study. Clin Neuropharmacol. 2019;42:117–22.

Article  PubMed  Google Scholar 

Roffman JL, Lamberti JS, Achtyes E, Macklin EA, Galendez GC, Raeke LH, et al. Randomized multicenter investigation of folate plus vitamin B12 supplementation in schizophrenia. JAMA Psychiatry. 2013;70:481–9.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Roffman JL, Petruzzi LJ, Tanner AS, Brown HE, Eryilmaz H, Ho NF, et al. Biochemical, physiological and clinical effects of l-methylfolate in schizophrenia: a randomized controlled trial. Mol Psychiatry. 2018;23:316–22.

Article  CAS  PubMed  Google Scholar 

Berk M, Copolov D, Dean O, Lu K, Jeavons S, Schapkaitz I, et al. N-acetyl cysteine as a glutathione precursor for schizophrenia-a double-blind, randomized, placebo-controlled trial. Biol Psychiatry. 2008;64:361–8.

Article  CAS  PubMed  Google Scholar 

Krivoy A, Onn R, Vilner Y, Hochman E, Weizman S, Paz A, et al. Vitamin D supplementation in chronic schizophrenia patients treated with clozapine: a randomized, double-blind, placebo-controlled clinical trial. EBioMedicine. 2017;26:138–45.

Article  PubMed  PubMed Central  Google Scholar 

Sepehrmanesh Z, Heidary M, Akasheh N, Akbari H, Heidary M. Therapeutic effect of adjunctive N-acetyl cysteine (NAC) on symptoms of chronic schizophrenia: a double-blind, randomized clinical trial. Prog Neuro-Psychopharmacol Biol Psychiatry. 2018;82:289–96.

Article  CAS  Google Scholar 

Sheikhmoonesi F, Zarghami M, Mamashli S, Charati JY, Hamzehpour R, Fattahi S, et al. Effectiveness of vitamin D supplement therapy in chronic stable schizophrenic male patients: a randomized controlled trial. Iran J Pharm Res. 2016;15:941–50.

CAS  PubMed  PubMed Central  Google Scholar 

Farokhnia M, Azarkolah A, Adinehfar F, Khodaie-Ardakani MR, Hosseini SM, Yekehtaz H, et al. N-acetylcysteine as an adjunct to risperidone for treatment of negative symptoms in patients with chronic schizophrenia: a randomized, double-blind, placebo-controlled study. Clin Neuropharmacol. 2013;36:185–192.

Article  CAS  PubMed  Google Scholar 

Breier A, Liffick E, Hummer TA, Vohs JL, Yang Z, Mehdiyoun NF, et al. Effects of 12-month, double-blind N-acetyl cysteine on symptoms, cognition and brain morphology in early phase schizophrenia spectrum disorders. Schizophr Res. 2018;199:395–402.

Article  PubMed  Google Scholar 

Qiao Y, Liu CP, Han HQ, Liu FJ, Shao Y, Xie B. No impact of omega-3 fatty acid supplementation on symptoms or hostility among patients with schizophrenia. Front Psychiatry. 2020;11:312.

Peet M, Brind J, Ramchand CN, Shah S, Vankar GK. Two double-blind placebo-controlled pilot studies of eicosapentaenoic acid in the treatment of schizophrenia. Research. 2001;49:243–51.

CAS  Google Scholar 

Peet M, Horrobin DF. A dose-ranging exploratory study of the effects of ethyl-eicosapentaenoate in patients with persistent schizophrenic symptoms. J Psychiatr Res. 2002;36:7–18.

Article  PubMed  Google Scholar 

Pawełczyk T, Grancow-Grabka M, Kotlicka-Antczak M, Trafalska E, Pawełczyk A. A randomized controlled study of the efficacy of six-month supplementation with concentrated fish oil rich in omega-3 polyunsaturated fatty acids in first episode schizophrenia. J Psychiatr Res. 2016;73:34–44.

Article  PubMed  Google Scholar 

Jamilian H, Ghaderi A. The effects of probiotic and selenium co-supplementation on clinical and metabolic scales in chronic schizophrenia: a randomized, double-blind, placebo-controlled trial. Biol Trace Elem Res. 2021;199:4430–8.

Article  CAS